Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Active, not recruiting · NCT06164275 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-07-13 | NCT06164275 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| Northwestern University | 381 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cadence Health - CDH | Warrenville | United States | 1 |
| Northwestern Delnor IL258 | Geneva | United States | 1 |
| Northwestern University | Chicago | United States | 727 |
| Stanford Cancer Center | Stanford | United States | 1 |